RUDR

Rudr Therapeutics is a pre-clinical stage biotechnology company focused on the discovery and development of small molecule inhibitors for oncology. The company utilizes a proprietary platform that combines chemical genetics and structural biology to identify allosteric binding sites on previously undruggable targets. Their primary focus is on the RAS/MAPK signaling pathway, with a lead program targeting SHP2 to treat various solid tumors. By developing highly selective allosteric modulators, Rudr aims to provide new therapeutic options that overcome resistance to existing cancer treatments. The company was founded on pioneering research from the Icahn School of Medicine at Mount Sinai.